Does Kaiser Permanente Cover Zepbound?

Kaiser Permanente's Formulary Position on Zepbound

Kaiser Permanente runs one of the most tightly controlled formularies among major U.S. health plans, and Zepbound (tirzepatide for chronic weight management) sits outside the standard drug list in most Kaiser regions. The plan's integrated HMO model means prescriptions must originate from Kaiser-employed or Kaiser-contracted physicians and be filled at Kaiser pharmacies.

This closed system creates a distinct challenge for members seeking Zepbound. Unlike open-network insurers where any in-network provider can prescribe and any participating pharmacy can fill, Kaiser controls both the clinical decision and the dispensing pathway. The FDA approved tirzepatide for chronic weight management in November 2023 under the brand name Zepbound, but formulary inclusion decisions at Kaiser operate on a separate timeline from FDA approvals.

Kaiser's Pharmacy and Therapeutics (P&T) committees evaluate new drugs based on clinical evidence, cost-effectiveness relative to existing formulary options, and population-level budget impact. Tirzepatide's list price of $1,059.87 per month places it among the higher-cost anti-obesity medications, and Kaiser's P&T committees have historically moved slowly on adding branded anti-obesity agents. The plan's regional structure also means formulary decisions can differ between Kaiser Permanente Northern California, Southern California, Colorado, the Northwest, and other regions. Members should verify their specific region's drug list through kp.org or by calling the pharmacy benefits number on their member ID card.

What the Clinical Evidence Shows

Zepbound's efficacy data comes primarily from the SURMOUNT trial program, and the numbers are substantial. In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg achieved 20.9% mean body weight reduction at 72 weeks compared to 3.1% with placebo [1]. The 10 mg dose produced 19.5% reduction, and the 5 mg dose produced 15.0% reduction. These results exceed what any previously approved anti-obesity medication demonstrated in phase 3 trials.

The dual GIP/GLP-1 receptor agonist mechanism distinguishes tirzepatide from single-target GLP-1 receptor agonists like semaglutide. A 2023 analysis published in JAMA comparing tirzepatide and semaglutide trial populations found that tirzepatide-treated patients lost approximately 5 to 6 additional percentage points of body weight [2]. This difference matters clinically: more patients crossed the 20% weight-loss threshold associated with resolution of type 2 diabetes, obstructive sleep apnea, and osteoarthritis symptoms.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option alongside semaglutide 2.4 mg, noting that "the choice between agents should be individualized based on efficacy, tolerability, cost, and access" [3]. This guideline language can support prior authorization requests and appeals, since it positions tirzepatide as a guideline-endorsed treatment rather than an experimental or cosmetic option.

Prior Authorization Requirements at Kaiser

Getting Zepbound approved through Kaiser's prior authorization process demands more documentation than most commercial insurers require. The pathway is internal-only.

Here is what the process typically involves. First, the member's primary care physician must place an internal referral to Kaiser's obesity medicine or endocrinology department. A Kaiser specialist then evaluates whether the member meets clinical criteria. Those criteria generally include a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documented participation in a Kaiser-supervised lifestyle modification program for at least 6 months, and documented trial-and-failure or contraindication to at least one formulary-preferred weight management medication.

The formulary-preferred agents vary by region but commonly include orlistat, phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and in some regions, semaglutide 2.4 mg (Wegovy). Kaiser may require failure of one or two of these before considering Zepbound.

"Trial and failure" typically means the member used the medication at an adequate dose for an adequate duration (usually 12 weeks minimum) and either did not achieve at least 5% body weight loss or experienced intolerable side effects that were documented in the medical record. Vague statements like "the patient didn't tolerate it" are insufficient. Specific adverse events, dates of medication starts and stops, and measured weight changes strengthen the request considerably.

Processing times for Kaiser prior authorizations average 5 to 15 business days, though urgent requests can receive faster review. Members should ask their Kaiser provider to submit the request electronically through Kaiser's internal pharmacy authorization system rather than by fax, which can add days to the review.

Step Therapy: What Kaiser Requires You to Try First

Kaiser Permanente applies step therapy to virtually all non-formulary anti-obesity medications. This is not optional.

The typical step-therapy sequence begins with structured lifestyle intervention through Kaiser's weight management programs, which include dietary counseling, exercise prescriptions, and behavioral health support. Kaiser considers this step zero, and documentation of participation is a prerequisite for any pharmacotherapy request. The plan's integrated care model was designed around this sequential approach [4].

Step one involves trying a formulary-preferred medication. In most Kaiser regions, this means orlistat (available as generic or OTC Alli) or phentermine-topiramate. Some regions have added semaglutide to their formulary, which can complicate the path to Zepbound since Kaiser may argue that another GLP-1-class agent already provides adequate coverage for incretin-based weight management.

Step two, required in some but not all regions, involves trying a second formulary-preferred agent if the first one fails. Only after completing these steps and documenting inadequate response does the pathway open for non-formulary agents like Zepbound.

One clinical strategy worth discussing with your Kaiser provider: if you have comorbid type 2 diabetes, tirzepatide is also available as Mounjaro for glycemic management. Kaiser formulary committees in several regions have added Mounjaro to their diabetes formularies. Although Mounjaro and Zepbound contain the same molecule (tirzepatide), they carry different NDC numbers and different approved indications. A Kaiser endocrinologist may be able to prescribe Mounjaro for type 2 diabetes management when Zepbound for weight management is not covered. This approach only applies to members with a documented type 2 diabetes diagnosis.

How to Appeal a Kaiser Permanente Denial of Zepbound

A denial is not the end. Kaiser members have a structured appeal process, and external data suggests that anti-obesity medication appeals succeed at meaningful rates when properly documented.

The first step is an internal grievance filed through Kaiser member services. Call the number on your member ID card and request a formal grievance review of the pharmacy denial. In this appeal, include the following: your complete weight history, BMI documentation, a list of all weight-related comorbidities with diagnostic codes, records of prior weight management attempts (both lifestyle and pharmacological), your prescribing physician's letter of medical necessity, and citations from clinical guidelines supporting tirzepatide as appropriate for your clinical situation.

The Endocrine Society guideline referenced above is especially useful in appeals because it explicitly lists tirzepatide among recommended first-line agents [3]. Citing the SURMOUNT-1 results showing 20.9% weight loss at the highest dose provides concrete efficacy data [1].

If Kaiser denies the internal appeal, members in California can file a complaint with the Department of Managed Health Care (DMHC), which has authority to order an Independent Medical Review (IMR). The DMHC's IMR process is free to the member and is conducted by physicians not affiliated with Kaiser. Data from the DMHC shows that independent reviewers overturn plan denials in a significant proportion of cases involving medications with strong clinical evidence [5]. Members in other states should contact their state's department of insurance or managed care for the equivalent external review process.

Timeline matters. Kaiser must respond to internal grievances within 30 days for standard requests and 72 hours for urgent requests. State IMR processes typically add another 30 to 45 days.

Cost Considerations and Savings Options

Without Kaiser coverage, Zepbound carries a list price of $1,059.87 per month. That adds up to approximately $12,718 per year. Cost is the primary barrier.

Eli Lilly offers the Zepbound Savings Card, which can reduce out-of-pocket costs to as little as $25 per month for commercially insured patients. The problem: Kaiser operates a closed pharmacy network, and manufacturer copay cards are typically not accepted at Kaiser pharmacies. Members who fill prescriptions exclusively through Kaiser's system cannot use the savings card.

Some potential workarounds exist but require careful navigation. If your Kaiser plan includes an out-of-network pharmacy benefit (which some employer-sponsored Kaiser plans do), you may be able to fill a Zepbound prescription at a non-Kaiser pharmacy and apply the savings card there. Check your Evidence of Coverage document or call Kaiser member services to determine whether your specific plan includes any out-of-network pharmacy provisions.

Eli Lilly also launched the LillyDirect platform and its associated telehealth vial program, offering tirzepatide single-dose vials at reduced prices compared to the autoinjector pen. As of early 2026, single-dose vials are priced at $399 per month for the maintenance doses. This cash-pay option bypasses insurance entirely and does not require Kaiser authorization, though it also means paying out of pocket.

For members with Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs), Zepbound prescriptions are eligible expenses when prescribed for a medical indication. An IRS determination confirmed that FDA-approved anti-obesity medications prescribed by a physician qualify as deductible medical expenses [6].

Kaiser's Evolving Approach to Anti-Obesity Pharmacotherapy

Kaiser's coverage policies for anti-obesity medications have shifted in the past three years, and the direction favors broader access.

In 2023, fewer than 30% of large commercial health plans covered any GLP-1 receptor agonist for weight management. By mid-2025, that number exceeded 55%, according to survey data from the Kaiser Family Foundation (a separate organization from Kaiser Permanente) [7]. Kaiser Permanente, as both an insurer and a care delivery system, faces dual pressure: the clinical evidence strongly supports these medications, and member demand continues to grow.

Several factors may accelerate Kaiser's formulary expansion. First, generic competition is anticipated: the earliest potential generic tirzepatide entry is projected for the late 2020s, though patent litigation could alter that timeline. Second, outcomes data from real-world Kaiser patient populations using GLP-1 agonists for diabetes may demonstrate cardiovascular and renal benefits that shift the cost-effectiveness calculation. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease [8]. While SELECT studied semaglutide rather than tirzepatide, the cardiovascular benefit signal across the incretin class strengthens the argument for broader formulary inclusion of all drugs in this category.

Third, state legislative activity matters. California's SB 135 and similar bills in other states have proposed mandating coverage of FDA-approved anti-obesity medications, which would directly affect Kaiser Permanente's formulary decisions in those states. Members can check their state legislature's website for the current status of anti-obesity medication coverage mandates.

Comparing Kaiser to Other Major Insurers

Kaiser's restrictive approach to Zepbound stands in contrast to several other large insurers that have moved toward coverage in 2025 and 2026.

UnitedHealthcare, the largest commercial insurer, added tirzepatide to many employer-sponsored formularies with prior authorization in 2025. Aetna and Cigna have similarly expanded coverage for tirzepatide under both the Mounjaro (diabetes) and Zepbound (weight management) labels. Blue Cross Blue Shield plans vary by state, but multiple BCBS affiliates now cover Zepbound with step therapy through a GLP-1 agonist.

Kaiser's unique position as an integrated delivery system means the plan bears the full cost of the medication rather than sharing it across a pharmacy benefit manager, pharmacy network, and health plan. This integrated cost structure makes Kaiser more sensitive to high-cost specialty medications, but it also means Kaiser captures the downstream savings from reduced bariatric surgeries, fewer obesity-related hospitalizations, and improved chronic disease management. A 2024 study in Obesity estimated that anti-obesity medication use in integrated health systems could reduce total medical costs by $2,400 to $5,800 per treated patient per year after accounting for drug costs [9].

Kaiser members who feel that the plan's current formulary position does not reflect the clinical evidence have several advocacy options: filing formal grievances, contacting their state's department of managed care, joining patient advocacy groups like the Obesity Action Coalition, and engaging their employer's benefits team if they have employer-sponsored Kaiser coverage. Employers can negotiate formulary additions during annual plan renewal.